What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
A multicentre, proof-of-concept trial of suggests that low-dose IL-2 therapy may be effective in moderate-to-severe systemic lupus erythematosus (SLE). This is not surprising as IL-2 is needed to bolster insufficient regulatory T cell (Treg) activity, thought to be pivotal to the pathophysiology of SLE.
A wide range of therapies have been implicated in causing drug-induced lupus erythematosus (DIL); now it appears that proton pump inhibitors (PPIs) can be added to the list of causative drugs.
Dr. John Cush RheumNow
3 years 4 months ago
Survey of 3357 retired Olympians (45 yrs) shows same OA rates as 1735 gen population (41yrs) - #OA in 23% (knee 7.4%, hip, ankle). OA from Injury, age, obesity. Prior knee/hip injury increased OA rates significantly (aOR 1.51/4.03) https://t.co/yZAHA8MYly https://t.co/W1StoLYjkl
Dr. John Cush RheumNow
3 years 4 months ago
NEJM Clinical Images: 74-yoF with psoriatic arthritis has swelling of the fifth finger; found to have nontender, subcutaneous nodules in the hypothenar region and over the fifth finger. https://t.co/leVXN4WNXx https://t.co/5S5nD8ZgcQ
Dr. John Cush RheumNow
3 years 4 months ago
Study of 209 Early RA (<1yr) pts found 23 (11%) with Drug Free Remission (DFR) after 74 mos of F/U; DFR maintained x 48 mo (18–82). DFR was assoc w/ early persistence on Therapy (HR 3.84). Adhering to prescribed treatment may lead to DFR https://t.co/oO8wKOKfxE https://t.co/DPX9JudplX
Avraham Z. Cooper, MD AvrahamCooperMD
3 years 4 months ago
Popeye sign (=biceps tendon rupture)
#MedTwitter https://t.co/vES4juLCUp
Christine Peoples CPeoplesMD
3 years 4 months ago
Exciting news to announce! Our book "Telerheumatology: Origins, Current Practice, and Future Directions" is now available for download and has been published on SpringerLink. #telerheumatology #rheumtwitter #rheum https://t.co/rW0g6WByTp
Dr. John Cush RheumNow
3 years 4 months ago
Mass Gen Brigham study of Rheum (SARD) pts COVID severity over time (3/20-1/22) shows less severe COVID over time. 1449 SARD pts had COVID-19 (1/3 RA); 28% severe. Early COVID was more severe (46%) vs 15% w/ Omicron. Unvax were more severe (78% v 60%) https://t.co/DTge2od82Q https://t.co/LXeujT6zd5
TheDaoIndex KDAO2011
3 years 4 months ago
Has insurance moved to a new tactic to intimidate doctors from appeals? I was expecting to do a peer to peer to get #Xeljanz approved, they put me on the phone with a courtroom judge to make me swear I am telling the truth about why the medicine is needed for the patient.
Pregnancy often occurs in women with axial spondyloarthritis (axSpA), and a recent cohort study suggests outcomes are generally better than what had been reported in the literature.
Data was collected from axSpA patients from 4 registries who were pregnant. This included a total of 332 pregnancies from 304 axSpA women (mean age 31 years; disease duration 5 years). Recorded outcomes included:
Dr. John Cush RheumNow
3 years 4 months ago
Biosimilar switching is due to costs, formulary, relocation. Study of 23 studies, 3657 pts found only observational data, no RCTs. Ref product to biosimilar usually RCTs; Biosimilar switches usually real world evidence w/ good efficacy & no new risks. https://t.co/odAYHdbVd1 https://t.co/BabkVYsMBL
JUNIPERA study evaluated secukinumab (SEC) in children with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) and was found to be safe and effective in patients with active ERA and JPsA who previous failed to respond to conventional therapy.
Dr. John Cush RheumNow
3 years 4 months ago
Are you a fan of the RheumNow podcast? Please rate, like and review us wherever you get your podcast. We'd appreciate it!
Dr. John Cush RheumNow
3 years 4 months ago
Recurrence of axSpA in 1st-degree relatives (FDR) probands w/ 35-yrs F/U. From 363 AS probands & 806 FDR, 27.1% of B27(+) FDR developed axSpA; 18.2% from AS probands; 4% from nr-axSpA probands. Recurrence higher with B27+ probands https://t.co/1xczXdtrH3 https://t.co/mXZ72nVAqp
Dr. John Cush RheumNow
3 years 4 months ago
UK Women’s Cohort -diet & Hip Fx risk study shows that amongst 26,318 women, 822 hip Fxs - Hip Fx risk was higher in Vegetarians (HR 1.33; 1.03, 1.71)) but not meat-eaters (HR 1.00; 0.85, 1.18) or pescatarians (0.97; 0.75, 1.26); unaffected by BMI https://t.co/tipy0IBp4D https://t.co/sG0lJAUgDj
Poster Hall